The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

Author(s):

Gabriel Pardo, MD, FAAN,Martin Belkin, DO

Key Takeaways

Biomarkers have improved diagnostic accuracy and enabled earlier intervention in multiple sclerosis, enhancing patient outcomes.
Highly efficacious disease-modifying therapies have transformed treatment paradigms, offering better control over disease progression and relapse rates.
Personalized treatment strategies have emerged, optimizing patient outcomes through a more tailored approach in MS management.

Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.

EP: 1.Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024

Now Viewing

EP: 2.The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

Video content above is prompted by the following:

Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.